1.In Vitro Amphotericin B Susceptibility of Korean Bloodstream Yeast Isolates Assessed by the CLSI Broth Microdilution Method, Etest, and Minimum Fungicidal Concentration Test.
Ji Young PARK ; Jong Hee SHIN ; Young UH ; Eui Chong KIM ; Seung Jung KEE ; Soo Hyun KIM ; Myung Geun SHIN ; Soon Pal SUH ; Dong Wook RYANG
The Korean Journal of Laboratory Medicine 2008;28(5):346-352
BACKGROUND: Although amphotericin B (AMB) has a wide spectrum of activity that encompasses the majority of yeast isolates, there have been recent reports suggesting that some yeast isolates exhibit decreased susceptibility to AMB. However, in vitro AMB susceptibility of yeast species isolates from blood cultures in Korea has not been fully surveyed. METHODS: A total of 92 bloodstream yeast isolates from four Korean hospitals, representing 10 Candida species (69 isolates) and 4 non-Candida yeast species (23 isolates) were evaluated. AMB minimum inhibitory concentrations (MICs) were determined by two methods: the CLSI method and Etest. AMB minimum fungicidal concentrations (MFCs) were also determined. RESULTS: For all 92 yeast isolates, the CLSI method generated a restricted range of MICs (0.125 to 4 microgram/mL) with 3.3% exhibiting MICs > or =2 microgram/mL, and the corresponding MFC values ranged from 0.25 to 8 microgram/mL with 26.1% showing MFCs > or =2 microgram/mL. Etest produced the widest distribution of MICs, ranging from 0.03 to 32 microgram/mL. High AMB MICs (> or =0.38 microgram/mL) by Etest was observed in 34.8% of the isolates: Candida krusei (100%), Candida rugosa (100%), Trichosporon asashii (100%), Candida glabrata (82%), and Yarrowia lipolytica (75%). Etest disclosed that all isolates of Candida guilliermondii, Candida lusitaniae, Candida pelliculosa and Kodamaea ohmeri were highly susceptible to AMB (MIC < or =0.19 microgram/mL). CONCLUSIONS: Our study showed that Etest may be more useful to discriminate yeast isolates with reduced susceptibility to AMB, and some isolates of less common yeast species from Korea may have decreased AMB susceptibilities.
Amphotericin B/*pharmacology
;
Antifungal Agents/*pharmacology
;
Candida/drug effects/isolation & purification
;
Candidiasis/microbiology
;
Culture Media
;
Humans
;
Korea
;
Microbial Sensitivity Tests
;
Reagent Kits, Diagnostic
;
Yeasts/*drug effects/isolation & purification
2.In vitro activities of antifungal drugs against yeasts isolated from blood cultures and moulds isolated from various clinically significant sites in Singapore.
Annals of the Academy of Medicine, Singapore 2008;37(10):841-846
INTRODUCTIONFungaemia carries with it high mortality rates and appropriate as well as timely antifungal therapy has been shown to be life saving.
MATERIALS AND METHODSWe studied the invitro activities of antifungal agents using the Etest method, against 100 Candida isolates from blood cultures, 10 Cryptococcus isolates from blood or cerebrospinal fluid and 50 mould isolates from various clinically significant sites of patients in Singapore General Hospital, from June 2004 to December 2006.
RESULTSOverall, the yeasts appeared to have low minimum inhibitory concentrations (MICs) for all the 5 antifungal drugs tested except for fluconazole. The overall high MIC90 values of the moulds against the azoles were largely attributed to the non-Aspergillus moulds. Posaconazole, itraconazole, voriconazole and caspofungin appear effective against local strains of Aspergillus species, although there are no interpretive breakpoints.
CONCLUSIONSThe results show that the local fungal strains studied appear to be susceptible to the usual antifungal drugs recommended in the literature.
Antifungal Agents ; pharmacology ; therapeutic use ; Candida ; drug effects ; isolation & purification ; Candidiasis ; microbiology ; Cryptococcosis ; microbiology ; Cryptococcus ; drug effects ; isolation & purification ; Fungemia ; drug therapy ; microbiology ; Fungi ; drug effects ; Hospitals, Public ; Humans ; Microbial Sensitivity Tests ; methods ; Reproducibility of Results ; Singapore ; Yeasts ; drug effects
3.Species Distribution and Antifungal Susceptibilities of Yeast Clinical Isolates from Three Hospitals in Korea, 2001 to 2007.
Mi Kyung LEE ; Dongeun YONG ; Myungsook KIM ; Mi Na KIM ; Kyungwon LEE
The Korean Journal of Laboratory Medicine 2010;30(4):364-372
BACKGROUND: We utilized results from the ARTEMIS DISK Global Antifungal Surveillance Program to evaluate the species distribution and fluconazole and voriconazole susceptibilities of yeast isolates from clinical specimens in South Korea from 2001 to 2007. METHODS: Data were collected on 5,665 yeast isolates from all body sites at three locations. All investigators tested clinical yeast isolates using the CLSI M44-A disk diffusion method. Test plates were automatically read and results were recorded using the BIOMIC image analysis plate reader system (Giles Scientific, USA). Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly via e-mail for analysis. RESULTS: Candida albicans was the most common isolate, but a progressive increase in non-C. albicans Candida and noncandidal yeast species has been observed in recent years. The overall percentages of isolates in each category (susceptible, susceptible dose dependent, and resistant) were 98.8%, 0.5%, and 0.7% and 99.2%, 0.2%, and 0.6% for fluconazole and voriconazole, respectively. Candida of 3 species exhibited decreased susceptibility to fluconazole (<90% S) in the order of that seen with the resistant (R) species: C. krusei, C. guilliermondii, and C. glabrata. Emerging resistance to fluconazole or voriconazole was documented among isolates of Cryptococcus neoformans, Trichosporon spp., and Rhodotorula spp. CONCLUSIONS: The species distribution and antifungal susceptibilities of yeasts may differ according to specimen type, testing method, hospital, and geographic region. Therefore, further large-scaled, long-term surveillance studies are needed to isolate yeasts and to confirm the species distribution and antifungal susceptibilities of yeast isolates from clinical specimens in Korea.
Antifungal Agents/*pharmacology
;
Candida/isolation & purification
;
Cryptococcus neoformans/isolation & purification
;
Disk Diffusion Antimicrobial Tests
;
*Drug Resistance, Fungal
;
Fluconazole/pharmacology
;
Hospitals
;
Humans
;
Pyrimidines/pharmacology
;
Republic of Korea
;
Rhodotorula/isolation & purification
;
Triazoles/pharmacology
;
Trichosporon/isolation & purification
;
Yeasts/*drug effects/isolation & purification
4.Purification and characterization of recombinant murine endostatin in E. coli.
Weon Kyoo YOU ; Seung Ho SO ; Hyosil LEE ; Sun Young PARK ; Mi Ran YOON ; Soo Ik CHANG ; Hyun Kyung KIM ; Young Ae JOE ; Yong Kil HONG ; Soo Il CHUNG
Experimental & Molecular Medicine 1999;31(4):197-202
Endostatin, a carboxyl-terminal fragment of collagen XVIII is known as an anti-angiogenic agent, that specifically inhibits the proliferation of endothelial cell and the growth of several primary tumor. We report here the purification and characterization of the recombinant murine endostatin (rmEndostatin) which was expressed in a prokaryotic expression system. This rmEndostatin has similar physiochemical properties of yeast-produced recombinant endostatin, and it also specifically inhibits the proliferation and migration of bovine capillary endothelial cells stimulated by basic fibroblast growth factor. The biological activity of rmEndostatin was also shown by its anti-angiogenic ability on the chorioallantoic membrane of chick embryo in vivo. In this article, we demonstrate the refolding and purification of rmEndostatin, expressed using E. coli system, to a biologically active and soluble form. In addition, these results confirm the activity of endostatin as a potent anti-angiogenic agent. Copyright 2000 Academic Press.
Angiogenesis Inhibitors/pharmacology*
;
Angiogenesis Inhibitors/isolation & purification
;
Angiogenesis Inhibitors/genetics*
;
Animal
;
Blotting, Western
;
Cattle
;
Cell Movement/drug effects
;
Chick Embryo
;
Chorion/pathology
;
Chorion/drug effects
;
Circular Dichroism
;
Collagen/pharmacology*
;
Collagen/isolation & purification
;
Collagen/genetics*
;
Electrophoresis, Polyacrylamide Gel
;
Endothelium, Vascular/drug effects
;
Endothelium, Vascular/cytology
;
Escherichia coli/genetics*
;
Fibroblast Growth Factor, Basic/pharmacology
;
Mice
;
Neovascularization, Physiologic/drug effects
;
Peptide Fragments/pharmacology*
;
Peptide Fragments/isolation & purification
;
Peptide Fragments/genetics*
;
Protein Folding
;
Recombinant Proteins/pharmacology
;
Recombinant Proteins/isolation & purification
;
Recombinant Proteins/genetics
;
Solubility
;
Yeasts/genetics